Symbols / DERM
DERM Chart
About
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Emrosi for the treatment of inflammatory lesions of rosacea, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 289.00M |
| Enterprise Value | 236.44M | Income | -8.66M | Sales | 59.40M |
| Book/sh | 0.98 | Cash/sh | 0.92 | Dividend Yield | — |
| Payout | 0.00% | Employees | 41 | IPO | — |
| P/E | — | Forward P/E | -144.83 | PEG | — |
| P/S | 4.87 | P/B | 8.85 | P/C | — |
| EV/EBITDA | -178.98 | EV/Sales | 3.98 | Quick Ratio | 1.08 |
| Current Ratio | 1.42 | Debt/Eq | 97.69 | LT Debt/Eq | — |
| EPS (ttm) | -0.35 | EPS next Y | -0.06 | EPS Growth | — |
| Revenue Growth | 20.50% | Earnings | 2026-03-26 | ROA | -4.60% |
| ROE | -47.05% | ROIC | — | Gross Margin | 66.05% |
| Oper. Margin | -8.67% | Profit Margin | -14.58% | Shs Outstand | 27.26M |
| Shs Float | 16.95M | Short Float | 11.71% | Short Ratio | 18.42 |
| Short Interest | — | 52W High | 9.55 | 52W Low | 4.97 |
| Beta | 0.82 | Avg Volume | 131.16K | Volume | 19.67K |
| Target Price | $13.50 | Recom | Strong_buy | Prev Close | $8.70 |
| Price | $8.69 | Change | -0.11% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$13.50
Mean price target
2. Current target
$8.70
Latest analyst target
3. DCF / Fair value
$-10.55
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.70
Low
$12.00
High
$16.00
Mean
$13.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-08-25 | init | HC Wainwright & Co. | — → Buy | $13 |
| 2025-08-13 | main | Lake Street | Buy → Buy | $13 |
| 2025-07-30 | main | B. Riley Securities | Buy → Buy | $12 |
| 2024-02-16 | init | Alliance Global Partners | — → Buy | $9 |
| 2023-09-07 | reit | B. Riley Securities | Buy → Buy | $6 |
| 2023-07-12 | main | B. Riley Securities | Buy → Buy | $6 |
| 2023-05-23 | main | B. Riley Securities | Buy → Buy | $3 |
| 2023-03-30 | reit | B. Riley Securities | — → Buy | $6 |
| 2022-02-25 | init | Cantor Fitzgerald | — → Overweight | $9 |
| 2021-12-16 | init | Roth Capital | — → Buy | $15 |
| 2021-12-07 | init | B. Riley Securities | — → Buy | $14 |
- (DERM) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily Fri, 20 Feb 2026 09
- From Biologics to Bio-Machines: Top Takeaways From Maui Derm 2026 - The American Journal of Managed Care® (AJMC®) ue, 03 Feb 2026 08
- Journey Medical Corporation (DERM) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance Wed, 12 Nov 2025 08
- Insiders Who Sold US$887k Of Journey Medical Made The Right Call - simplywall.st ue, 28 Oct 2025 07
- Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewswire Wed, 12 Nov 2025 08
- Journey Medical: Emrosi Is Winning, But The Stock Hasn't Noticed - Seeking Alpha hu, 22 Jan 2026 08
- Oddity’s Q3 Beat Signals Rise of Derm-Tech - BeautyMatter Fri, 21 Nov 2025 08
- B.Riley reiterates Buy rating on Journey Medical stock, maintains $12 target - Investing.com Wed, 04 Feb 2026 08
- DERM Stock Price, News & Analysis - Stock Titan Fri, 25 Apr 2025 00
- Optimizing Nonsurgical Management of Skin Tumors at Maui Derm 2026 - The American Journal of Managed Care® (AJMC®) Wed, 28 Jan 2026 08
- What drives DERM’s stock price - July 2025 PreEarnings & Consistent Profit Alerts - mfd.ru Fri, 20 Feb 2026 12
- 2025 FDA dermatology approvals: A new gene therapy and two targeted therapies - Managed Healthcare Executive ue, 09 Dec 2025 08
- What Makes Journey Medical Corporation (DERM) a Good Investment? - Yahoo Finance Wed, 19 Nov 2025 08
- Dermatologists Reveal the Best 2025 Amazon Prime Day Skin-Care Deals - NewBeauty ue, 07 Oct 2025 07
- How (DERM) Movements Inform Risk Allocation Models - Stock Traders Daily Mon, 09 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1250000 | 81250 | — | Conversion of Exercise of derivative security at price 0.06 per share. | MARAOUI CLAUDE | Chief Executive Officer | — | 2025-08-25 00:00:00 | D |
| 1 | 50000 | — | — | Stock Award(Grant) at price 0.00 per share. | ROSENWALD LINDSAY A | Director | — | 2025-08-05 00:00:00 | D |
| 2 | 20000 | — | — | Stock Award(Grant) at price 0.00 per share. | PEARCE MICHAEL COOPER | Director | — | 2025-08-05 00:00:00 | D |
| 3 | 20000 | — | — | Stock Award(Grant) at price 0.00 per share. | HERSKOWITZ NEIL | Director | — | 2025-08-05 00:00:00 | D |
| 4 | 20000 | — | — | Stock Award(Grant) at price 0.00 per share. | TOLEDANO MIRANDA JAYNE | Director | — | 2025-08-05 00:00:00 | D |
| 5 | 20000 | — | — | Stock Award(Grant) at price 0.00 per share. | SMITH JUSTIN ADAM | Director | — | 2025-08-05 00:00:00 | D |
| 6 | 7173 | — | — | Stock Award(Grant) at price 0.00 per share. | ROSENWALD LINDSAY A | Director | — | 2025-06-25 00:00:00 | D |
| 7 | 7173 | — | — | Stock Award(Grant) at price 0.00 per share. | PEARCE MICHAEL COOPER | Director | — | 2025-06-25 00:00:00 | D |
| 8 | 7173 | — | — | Stock Award(Grant) at price 0.00 per share. | HERSKOWITZ NEIL | Director | — | 2025-06-25 00:00:00 | D |
| 9 | 7173 | — | — | Stock Award(Grant) at price 0.00 per share. | TOLEDANO MIRANDA JAYNE | Director | — | 2025-06-25 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 1.17M | -698.46K | 0.00 | -2.70M |
| TaxRateForCalcs | 0.21 | 0.21 | 0.00 | 0.27 |
| NormalizedEBITDA | -13.96M | 5.25M | -23.09M | -22.78M |
| TotalUnusualItems | 5.56M | -3.33M | -89.00K | -9.99M |
| TotalUnusualItemsExcludingGoodwill | 5.56M | -3.33M | -89.00K | -9.99M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -14.67M | -3.85M | -29.63M | -43.99M |
| ReconciledDepreciation | 3.52M | 3.85M | 4.37M | 2.56M |
| ReconciledCostOfRevenue | 20.79M | 22.80M | 30.77M | 32.08M |
| EBITDA | -8.40M | 1.92M | -23.18M | -32.77M |
| EBIT | -11.91M | -1.93M | -27.55M | -35.33M |
| NetInterestIncome | -1.94M | -1.38M | -1.96M | -7.03M |
| InterestExpense | 2.70M | 1.70M | 2.02M | 7.03M |
| InterestIncome | 757.00K | 322.00K | 60.00K | 2.00K |
| NormalizedIncome | -19.07M | -1.23M | -29.54M | -36.70M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -14.67M | -3.85M | -29.63M | -43.99M |
| TotalExpenses | 74.36M | 78.11M | 101.19M | 88.47M |
| TotalOperatingIncomeAsReported | -13.68M | -2.07M | -27.52M | -34.88M |
| DilutedAverageShares | 20.43M | 18.23M | 17.53M | 10.19M |
| BasicAverageShares | 20.43M | 18.23M | 17.53M | 10.19M |
| DilutedEPS | -0.72 | -0.21 | -1.69 | -4.32 |
| BasicEPS | -0.72 | -0.21 | -1.69 | -4.32 |
| DilutedNIAvailtoComStockholders | -14.67M | -3.85M | -29.63M | -43.99M |
| NetIncomeCommonStockholders | -14.67M | -3.85M | -29.63M | -43.99M |
| NetIncome | -14.67M | -3.85M | -29.63M | -43.99M |
| NetIncomeIncludingNoncontrollingInterests | -14.67M | -3.85M | -29.63M | -43.99M |
| NetIncomeContinuousOperations | -14.67M | -3.85M | -29.63M | -43.99M |
| TaxProvision | 61.00K | 221.00K | 63.00K | 1.63M |
| PretaxIncome | -14.61M | -3.63M | -29.57M | -42.36M |
| OtherIncomeExpense | 5.56M | -3.33M | -89.00K | -9.99M |
| SpecialIncomeCharges | 5.68M | -3.14M | 0.00 | -9.54M |
| OtherSpecialCharges | -5.68M | 9.54M | ||
| ImpairmentOfCapitalAssets | 0.00 | 3.14M | 0.00 | |
| GainOnSaleOfSecurity | -116.00K | -183.00K | -89.00K | -447.00K |
| NetNonOperatingInterestIncomeExpense | -1.94M | -1.38M | -1.96M | -7.03M |
| InterestExpenseNonOperating | 2.70M | 1.70M | 2.02M | 7.03M |
| InterestIncomeNonOperating | 757.00K | 322.00K | 60.00K | 2.00K |
| OperatingIncome | -18.23M | 1.07M | -27.52M | -25.34M |
| OperatingExpense | 53.48M | 55.22M | 70.41M | 56.39M |
| DepreciationAmortizationDepletionIncomeStatement | 3.42M | 3.77M | ||
| DepreciationAndAmortizationInIncomeStatement | 3.42M | 3.77M | ||
| Amortization | 3.42M | 3.77M | ||
| AmortizationOfIntangiblesIncomeStatement | 3.42M | 3.77M | ||
| ResearchAndDevelopment | 9.86M | 7.54M | 10.94M | 16.56M |
| SellingGeneralAndAdministration | 40.20M | 43.91M | 59.47M | 39.83M |
| GrossProfit | 35.26M | 56.29M | 42.89M | 31.05M |
| CostOfRevenue | 20.88M | 22.89M | 30.77M | 32.08M |
| TotalRevenue | 56.13M | 79.18M | 73.67M | 63.13M |
| OperatingRevenue | 55.13M | 59.66M | 71.00M | 63.10M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 22.15M | 19.32M | 17.77M | 17.32M |
| ShareIssued | 22.15M | 19.32M | 17.77M | 17.32M |
| NetDebt | 4.57M | |||
| TotalDebt | 25.08M | 14.73M | 22.96M | 910.00K |
| TangibleBookValue | -11.79M | 63.00K | -10.21M | 29.49M |
| InvestedCapital | 44.95M | 34.97M | 39.76M | 42.85M |
| WorkingCapital | 13.00M | 14.59M | 10.85M | 32.88M |
| NetTangibleAssets | -11.79M | 63.00K | -10.21M | 29.49M |
| CapitalLeaseObligations | 201.00K | 108.00K | 191.00K | 98.00K |
| CommonStockEquity | 20.07M | 20.35M | 16.98M | 42.04M |
| TotalCapitalization | 44.95M | 34.97M | 36.81M | 42.04M |
| TotalEquityGrossMinorityInterest | 20.07M | 20.35M | 16.98M | 42.04M |
| StockholdersEquity | 20.07M | 20.35M | 16.98M | 42.04M |
| RetainedEarnings | -87.03M | -72.36M | -68.50M | -38.87M |
| AdditionalPaidInCapital | 107.09M | 92.70M | 85.48M | 80.92M |
| CapitalStock | 2.00K | 2.00K | 2.00K | 2.00K |
| CommonStock | 2.00K | 2.00K | 2.00K | 2.00K |
| TotalLiabilitiesNetMinorityInterest | 60.17M | 56.50M | 88.18M | 55.24M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 25.00M | 14.63M | 21.35M | 3.63M |
| OtherNonCurrentLiabilities | 1.41M | 3.63M | ||
| TradeandOtherPayablesNonCurrent | 8.00K | |||
| LongTermDebtAndCapitalLeaseObligation | 25.00M | 14.63M | 19.93M | 0.00 |
| LongTermCapitalLeaseObligation | 118.00K | 9.00K | 108.00K | 0.00 |
| LongTermDebt | 24.88M | 14.62M | 19.83M | |
| CurrentLiabilities | 35.17M | 41.87M | 66.83M | 51.61M |
| OtherCurrentLiabilities | 625.00K | 3.36M | 2.83M | 4.96M |
| CurrentDeferredLiabilities | 0.00 | 4.99M | 0.00 | |
| CurrentDebtAndCapitalLeaseObligation | 83.00K | 99.00K | 3.03M | 910.00K |
| CurrentCapitalLeaseObligation | 83.00K | 99.00K | 83.00K | 98.00K |
| CurrentDebt | 2.95M | 812.00K | ||
| LineOfCredit | 0.00 | 2.95M | 812.00K | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 3.38M | 3.37M | 2.59M | 2.70M |
| CurrentProvisions | 3.12M | 4.08M | 3.69M | 3.24M |
| PayablesAndAccruedExpenses | 27.96M | 30.96M | 49.71M | 39.80M |
| CurrentAccruedExpenses | 9.95M | 10.55M | 10.06M | 12.51M |
| InterestPayable | 404.00K | 22.00K | 160.00K | 0.00 |
| Payables | 18.01M | 20.41M | 39.65M | 27.29M |
| OtherPayable | 1.37M | 2.02M | 2.63M | 3.83M |
| DuetoRelatedPartiesCurrent | 528.00K | 195.00K | 413.00K | 641.00K |
| TotalTaxPayable | 60.00K | 53.00K | 35.00K | 8.00K |
| IncomeTaxPayable | 60.00K | 53.00K | 35.00K | 8.00K |
| AccountsPayable | 16.05M | 18.15M | 36.98M | 23.45M |
| TotalAssets | 80.24M | 76.85M | 105.16M | 97.28M |
| TotalNonCurrentAssets | 32.06M | 20.39M | 27.48M | 12.79M |
| OtherNonCurrentAssets | 6.00K | 95.00K | 150.00K | |
| NonCurrentDeferredAssets | 0.00 | |||
| NonCurrentDeferredTaxesAssets | 0.00 | |||
| GoodwillAndOtherIntangibleAssets | 31.86M | 20.29M | 27.20M | 12.55M |
| OtherIntangibleAssets | 31.86M | 20.29M | 27.20M | 12.55M |
| NetPPE | 199.00K | 101.00K | 189.00K | 89.00K |
| GrossPPE | 199.00K | 101.00K | 189.00K | 89.00K |
| OtherProperties | 199.00K | 101.00K | 189.00K | 89.00K |
| CurrentAssets | 48.18M | 56.45M | 77.68M | 84.49M |
| OtherCurrentAssets | 3.21M | 3.59M | 3.31M | 2.44M |
| PrepaidAssets | 2.44M | |||
| Inventory | 14.43M | 10.21M | 14.16M | 9.86M |
| InventoriesAdjustmentsAllowances | -513.00K | -305.00K | -429.00K | 0.00 |
| FinishedGoods | 11.38M | 4.99M | 7.74M | 4.29M |
| WorkInProcess | 367.00K | 884.00K | 395.00K | 0.00 |
| RawMaterials | 3.20M | 4.64M | 6.45M | 5.57M |
| Receivables | 10.23M | 15.22M | 28.21M | 23.11M |
| AccountsReceivable | 10.23M | 15.22M | 28.21M | 23.11M |
| AllowanceForDoubtfulAccountsReceivable | -600.00K | -500.00K | -400.00K | -100.00K |
| GrossAccountsReceivable | 10.83M | 15.72M | 28.61M | 23.21M |
| CashCashEquivalentsAndShortTermInvestments | 20.30M | 27.44M | 32.00M | 49.08M |
| CashAndCashEquivalents | 20.30M | 27.44M | 32.00M | 49.08M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -24.13M | 240.00K | -33.53M | -12.18M |
| RepaymentOfDebt | -1.25M | -51.95M | -7.86M | -11.49M |
| IssuanceOfDebt | 17.88M | 47.49M | 24.76M | 16.54M |
| IssuanceOfCapitalStock | 4.49M | 0.00 | 51.50M | |
| CapitalExpenditure | -15.00M | -5.00M | -20.00M | -10.00M |
| InterestPaidSupplementalData | 2.01M | 1.13M | 993.00K | 0.00 |
| IncomeTaxPaidSupplementalData | 125.00K | 181.00K | 168.00K | 158.00K |
| EndCashPosition | 20.30M | 27.44M | 32.00M | 49.08M |
| BeginningCashPosition | 27.44M | 32.00M | 49.08M | 8.25M |
| ChangesInCash | -7.13M | -4.56M | -17.08M | 40.84M |
| FinancingCashFlow | 16.99M | -4.80M | 16.46M | 53.02M |
| CashFlowFromContinuingFinancingActivities | 16.99M | -4.80M | 16.46M | 53.02M |
| NetOtherFinancingCharges | -50.00K | -471.00K | -585.00K | -3.55M |
| ProceedsFromStockOptionExercised | 416.00K | 121.00K | 142.00K | 7.00K |
| NetPreferredStockIssuance | 0.00 | 18.97M | ||
| PreferredStockIssuance | 0.00 | 18.97M | ||
| NetCommonStockIssuance | 4.49M | 0.00 | 32.54M | |
| CommonStockIssuance | 4.49M | 0.00 | 32.54M | |
| NetIssuancePaymentsOfDebt | 16.63M | -4.45M | 16.90M | 5.05M |
| NetShortTermDebtIssuance | 0.00 | -2.95M | 2.14M | 812.00K |
| ShortTermDebtPayments | 0.00 | -30.95M | -2.86M | -6.19M |
| ShortTermDebtIssuance | 0.00 | 28.00M | 5.00M | 7.00M |
| NetLongTermDebtIssuance | 16.63M | -1.51M | 14.76M | 4.24M |
| LongTermDebtPayments | -1.25M | -21.00M | -5.00M | -5.30M |
| LongTermDebtIssuance | 17.88M | 19.49M | 19.76M | 9.54M |
| InvestingCashFlow | -15.00M | -5.00M | -20.00M | -10.00M |
| CashFlowFromContinuingInvestingActivities | -15.00M | -5.00M | -20.00M | -10.00M |
| NetOtherInvestingChanges | -20.00M | |||
| NetIntangiblesPurchaseAndSale | -15.00M | -5.00M | -20.00M | -10.00M |
| PurchaseOfIntangibles | -15.00M | -5.00M | -20.00M | -10.00M |
| OperatingCashFlow | -9.13M | 5.24M | -13.53M | -2.18M |
| CashFlowFromContinuingOperatingActivities | -9.13M | 5.24M | -13.53M | -2.18M |
| ChangeInWorkingCapital | -3.77M | -1.66M | 6.19M | 14.71M |
| ChangeInOtherCurrentLiabilities | -96.00K | -83.00K | -95.00K | -84.00K |
| ChangeInOtherCurrentAssets | 6.00K | 0.00 | 55.00K | -144.00K |
| ChangeInPayablesAndAccruedExpense | -4.30M | -17.80M | 10.73M | 23.40M |
| ChangeInAccruedExpense | -2.21M | 606.00K | -3.64M | 3.10M |
| ChangeInInterestPayable | 382.00K | -138.00K | 160.00K | 0.00 |
| ChangeInPayable | -2.09M | -18.40M | 14.37M | 20.30M |
| ChangeInAccountPayable | -2.10M | -18.42M | 14.34M | 20.39M |
| ChangeInTaxPayable | 7.00K | 18.00K | 27.00K | -91.00K |
| ChangeInIncomeTaxPayable | 7.00K | 18.00K | 27.00K | -91.00K |
| ChangeInPrepaidAssets | 376.00K | -279.00K | -871.00K | -774.00K |
| ChangeInInventory | -4.22M | 3.95M | 1.74M | -8.46M |
| ChangeInReceivables | 4.47M | 12.55M | -5.38M | 768.00K |
| ChangesInAccountReceivables | 4.47M | 12.55M | -5.38M | 768.00K |
| OtherNonCashItems | 307.00K | 709.00K | 833.00K | 20.02M |
| StockBasedCompensation | 6.10M | 2.61M | 4.42M | 2.47M |
| AssetImpairmentCharge | 516.00K | 3.58M | 284.00K | 48.00K |
| DeferredTax | 0.00 | 1.57M | ||
| DeferredIncomeTax | 0.00 | 1.57M | ||
| DepreciationAmortizationDepletion | 3.52M | 3.85M | 4.37M | 2.56M |
| DepreciationAndAmortization | 3.52M | 3.85M | 4.37M | 2.56M |
| AmortizationCashFlow | 3.42M | 3.77M | 4.28M | 2.47M |
| AmortizationOfIntangibles | 3.42M | 3.77M | 4.28M | 2.47M |
| Depreciation | 91.00K | 88.00K | 88.00K | 86.00K |
| OperatingGainsLosses | -1.12M | 447.00K | ||
| GainLossOnInvestmentSecurities | 447.00K | |||
| NetIncomeFromContinuingOperations | -14.67M | -3.85M | -29.63M | -43.99M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for DERM
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|